Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trialChristoph Male, Philip Maes, Anthonie W.A. Lensing et al.|The Lancet Haematology|2019Cited by 329
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History StudyRachael F. Grace, Wilma Barcellini, Yaddanapudi Ravindranath et al.|Blood|2018Cited by 165
Genotype‐phenotype correlation and molecular heterogeneity in pyruvate kinase deficiencyPaola Bianchi, Rachael F. Grace, Elisa Fermo et al.|American Journal of Hematology|2020Cited by 66
Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History StudyEduard J. van Beers, Rachael F. Grace, Stephanie van Straaten et al.|Haematologica|2018Cited by 61
Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findingsAxel Schmidt, Fabian Brand, Magdalena Danyel et al.|Nature Genetics|2024Cited by 49